多肿瘤标志物蛋白芯片检测诊断肝癌的荟萃分析  

Protein Assay System of C12 Varied Tumor Markers in Liver Neoplasm Diagnosis:A Meta-analysis

作　　者：孙劦义[1] 鲍依稀[1] 赖思含[1] 李梦雅[1] 

机构地区：[1]重庆医科大学第二附属医院检验科,400016

出　　处：《中国医药指南》2010年第12期5-8,24,共5页Guide of China Medicine

基　　金：重庆市自然科学基金资助项目(CSTC2009BB5399)

摘　　要：目的系统评价多肿瘤标志物蛋白芯片检测诊断肝癌的意义。方法综合国内外2002至2009年关于C12多肿瘤标志物蛋白芯片检测比较诊断肝癌的文献,采用QUADAS进行质量评价,用MetaDisc1.4软件进行荟萃分析。结果纳入符合标准的16篇文献进行荟萃分析。异质性检验提示无阈值效应,但存在其他原因导致的异质性。C12多肿瘤标志物检测诊断肝癌的敏感度分别为0.859(0.837,0.878),特异度为0.812(0.797,0.827),阳性似然比为6.630(3.615,12.159),阴性似然比为0.192(0.150,0.247),诊断优势比为36.788(18.960,71.379),SROC曲线下面积(AUC)分别为0.8932,Q*指数为0.8579。结论C12多肿瘤标志物对肝癌的敏感度及诊断准确度高,可广泛推广使用C12多肿瘤标志物蛋白芯片检测系统对肝癌的诊断。Objective To systematic review of protein chip assay system of C 12 varied tumor markers in the diagnosis of liver neoplasm. Methods The studies about protein chip assay system of C12 varied tumor markers in the diagnosis of liver neoplasm were searched. Quality of included trials was assessed by quality assessment of diagnostic accuracy studies. The software Meta DiScl.4 was used to review management and data analysis. Results In total, 16 relevant studies were searched. Heterogeneity（except for threshold effect）was found within these studies. The sensitivity Protein Chip Assay System of C12 Varied tumor markers was 0.859（0.837, 0.878）, with specificity 0.812（0.797, 0.827）, and positive likelihood ratio （LR＋） of it was 6.630（3.615, 12.159）, with negative likelihood ratio （LR-） 0.192（0.150, 0.247）, diagnostic odds ratio（dOR） 36.788（18.960, 71.379）. Area under curve of SROC curve （AUC）of （C 12） was 0.8932, and Q index was 0.8579. Conclusions The performance of C12, with the high sensitivity, is higher in the diagnosis of liver neoplasm. We can widely promote the use of C 12 multi-tumor marker protein chip detection system for the diagnosis of liver cancer.

关 键 词：肿瘤标志物 甲胎蛋白 肿瘤 肝癌 蛋白芯片 

分 类 号：R730.4[医药卫生—肿瘤]